July 7, 2026

Don't miss out on our limited-time BOGO deal: Buy one year of STAT+, get one year free. Pay just $399 for 24 months of unlimited access to in-depth reporting, exclusive scoops, and expert analysis.

And be sure to read the first installments of our new series, Out of Pocket, Out of Reach, by Bob Herman below. His reporting chronicles how the cost of employer-based health insurance is crushing workers and businesses. Why has it become so unaffordable? — Sarah Mupo, director of editorial operations

Rachel Bernier-Green, founder of Thryvo Financial Advisory, outside her home office in Chicago.
Kayana Szymczak for STAT

STAT+ | America’s small businesses are giving up on health insurance

U.S. small businesses are offering health insurance to their workers at the lowest rate ever. See why in Part 1 of the series 'Out of Pocket, Out of Reach.'

By Bob Herman


STAT+ | For a Georgia entrepreneur, health coverage has never been affordable

Amy Bielawski is part of a trend. Rising health care costs are reshaping the labor market, and small businesses are where the change becomes visible first.

By Bob Herman


Opinion: What if this Ebola outbreak can’t be stopped?

If the Ebola outbreak isn’t extinguished, it could burn for decades, posing an ongoing threat to global health.

By Ivan Buendia Gayton and Eric D. Perakslis



Chris Deacon is an attorney and independent health insurance consultant who played a crucial role in New Jersey's state workers winning a $100 million fraud settlement.
KC Nwakalor for STAT

STAT+ | This whistleblower took on a health insurance giant and a political machine. She’s not stopping there

Chris Deacon's whistleblower crusade: America's workers and businesses are buckling under the weight of health care costs driven by industry profiteering.

By Bob Herman


Opinion: Medicine thinks Gen Z is too soft. It’s wrong

We can’t simultaneously count on Gen Z doctors to refill the workforce and dismiss them as too soft for it.

By Frantz M. Berthaud


STAT+ | FDA approves Vera Therapeutics kidney disease treatment

The drug was approved for the treatment of IgA nephropathy, a chronic autoimmune condition drawing wide interest from biotech companies.

By Adam Feuerstein


More around STAT

 
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.